A Phase 3 interventional study of TAK-438 and Lansoprazole in Duodenal Ulcer, sponsored by Takeda. Completed at 81 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-12.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Duodenal Ulcer by Takeda — none open to participants now, none under way, none of them phase 3. Duodenal Ulcer · Takeda.
Among the 18 studies in Duodenal Ulcer by Takeda, this one is the 4th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2017, is one of 11 in phase 3, and was the 14th registered.
79 studies on the registry are indexed under Duodenal Ulcer; 5 are open to participants now.
Browse Duodenal Ulcer studies →None of the 18 studies in Duodenal Ulcer by Takeda is open now. The open studies under Duodenal Ulcer, anywhere →
Of the 3 Duodenal Ulcer studies recruiting now, 1 sets no upper age limit and 2 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 533 is above the median of 308 across 54 interventional studies indexed under Duodenal Ulcer.
Median enrollment 439 across the 11 interventional studies, 1,304 across the 7 observational. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Duodenal Ulcer by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate the non-inferior efficacy of TAK-438 versus lansoprazole in the treatment of participants with duodenal ulcer.
The drug being tested in this study is called TAK-438. TAK-438 is being tested to treat people who have duodenal ulcers and also may or may not have Helicobacter pylori (HP) infection. This study will look at duodenal ulcer healing and also the elimination of HP in people who take TAK-438 versus lansoprazole. The study will enroll approximately 530 patients.
Participants were randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which remained undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):
HP+ participants will be asked to take a TAK- 438 tablet and a lansoprazole capsule twice daily in conjunction with bismuth-containing quadruple therapy for 2 weeks, followed up by a TAK-438 tablet and a lansoprazole capsule once daily for up to 4 weeks. HP negative (HP-) participants will be asked to take a TAK-438 tablet and a lansoprazole capsule once daily for up to 6 weeks.
This multi-center trial will be conducted China, Korea and Taiwan. The overall time to participate in this study is up to 10 weeks. Participants will make multiple visits plus final visit at 2 weeks or 4 weeks after last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Laboratory tests performed prior to randomization revealed any of the following abnormalities in the participant:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
H. pylori negative (HP -) participants: TAK-438 20 mg, tablets, orally, once daily (QD) and lansoprazole placebo-matching capsules, orally, QD for up to 6 weeks. H. pylori positive (HP +) participants: TAK-438 20 mg, tablets, orally, twice daily (BID) and lansoprazole placebo-matching capsules, orally, BID for first 2 weeks along with Bismuth-Containing Quadruple Therapy followed byTAK-438 20 mg, tablets, orally, QD and lansoprazole placebo-matching capsules, orally, QD for up to 4 weeks.
Drug: TAK-438 · Drug: Lansoprazole Placebo · Drug: Bismuth-Containing Quadruple Therapy
H. pylori negative (HP -) participants: lansoprazole 30 mg, capsules, orally, QD and TAK-438 placebo-matching tablets, orally, QD for up to 6 weeks. HP + participants: lansoprazole 30 mg, capsules, orally, BID and TAK-438 placebo-matching tablets, orally, BID for first 2 weeks along with Bismuth-Containing Quadruple Therapy followed by lansoprazole 30 mg, capsules, orally, QD and TAK-438 placebo-matching tablets, orally, BID for up to 4 weeks.
Drug: Lansoprazole · Drug: TAK-438 Placebo · Drug: Bismuth-Containing Quadruple Therapy
TAK-438 tablets
Also known as: Vonoprazan
Lansoprazole capsules
Also known as: Prevacid
TAK-438 placebo-matching tablets.
Lansoprazole placebo-matching capsules
1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
Percentage of Participants With Endoscopically Confirmed Healing of Duodenal Ulcers
Endoscopic healing was defined as the disappearance of all white coats associated with duodenal ulcers as confirmed endoscopically.
Time frame: Week 4 or Week 6
Percentage of Helicobacter Pylori Infected (HP+) Participants With Successful HP Eradication After 4 or 6 Weeks of Treatment
HP infection status was determined by \^13C Urea Breath Test (\^13C-UBT). The urea breath test is used to detect infection with HP, a bacteria associated with stomach ulcers, by testing individual breath samples in a central laboratory.
Time frame: 4 weeks post treatment (Up to 10 weeks)
Percentage of Participants With Endoscopically Confirmed Healing of Duodenal Ulcer at Week 4
Endoscopic healing is defined as the disappearance of all white coats associated with duodenal ulcers as confirmed endoscopically.
Time frame: Week 4
Percentage of Participants With Posttreatment Resolution of Gastrointestinal Symptoms Associated With Duodenal Ulcer at Weeks 2 Through 6
The percentage of participants with resolution of various gastrointestinal symptoms are reported as categories. Gastrointestinal symptoms included epigastric pain (postprandial, fasting, nocturnal), abdominal bloating, nausea/vomiting, heartburn and lack of appetite. The severity of subjective symptoms of erosive esophagitis were recorded as: none = 0, mild = 1, moderate = 2 or severe = 3.
Time frame: Week 2 up to Week 6
Participants took part in the study at 52 investigative sites in China, Korea, and Taiwan from 05 April 2017 to 19 July 2019.
| Milestone | TAK-438 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Started | 265 | 268 |
| Completed | 248 | 248 |
| Not completed | 17 | 20 |
| Withdrew: Randomized but not treated | 2 | 0 |
| Withdrew: Pretreatment event/adverse event | 5 | 10 |
| Withdrew: Significant protocol deviation | 2 | 3 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Voluntary withdrawal | 4 | 6 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Reason not specified | 1 | 0 |
Endoscopic healing was defined as the disappearance of all white coats associated with duodenal ulcers as confirmed endoscopically.
| percentage of participants | TAK-438 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Percentage of Participants With Endoscopically Confirmed Healing of Duodenal Ulcers | 96.9 (93.889 to 98.631) | 96.5 (93.406 to 98.374) |
HP infection status was determined by \^13C Urea Breath Test (\^13C-UBT). The urea breath test is used to detect infection with HP, a bacteria associated with stomach ulcers, by testing individual breath samples in a central laboratory.
| percentage of participants | TAK-438 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Percentage of Helicobacter Pylori Infected (HP+) Participants With Successful HP Eradication After 4 or 6 Weeks of Treatment | 91.5 (86.853 to 94.866) | 86.8 (81.330 to 91.093) |
Endoscopic healing is defined as the disappearance of all white coats associated with duodenal ulcers as confirmed endoscopically.
| percentage of participants | TAK-438 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Percentage of Participants With Endoscopically Confirmed Healing of Duodenal Ulcer at Week 4 | 89.2 (84.617 to 92.731) | 88.4 (83.830 to 92.124) |
The percentage of participants with resolution of various gastrointestinal symptoms are reported as categories. Gastrointestinal symptoms included epigastric pain (postprandial, fasting, nocturnal), abdominal bloating, nausea/vomiting, heartburn and lack of appetite. The severity of subjective symptoms of erosive esophagitis were recorded as: none = 0, mild = 1, moderate = 2 or severe = 3.
| percentage of participants | TAK-438 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Epigastric Pain (Postprandial) | 87.7 (76.321 to 94.917) | 91.8 (80.399 to 97.731) |
| Epigastric Pain (Fasting/Nocturnal) | 91.7 (85.579 to 95.767) | 90.1 (83.902 to 94.465) |
| Abdominal Bloating | 83.3 (69.778 to 92.519) | 87.3 (76.503 to 94.355) |
| Nausea/Vomiting | 85.2 (66.269 to 95.811) | 94.4 (72.706 to 99.859) |
| Heartburn | 100.0 (87.656 to 100.000) | 95.5 (77.156 to 99.885) |
| Lack of Appetite | 90.9 (70.839 to 98.879) | 100.0 (81.470 to 100.000) |
Collected over Up to Week 10 (Up to 6 weeks of treatment). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TAK-438 20 mg | 0/263 (0%) | 1/263 (0.4%) | 162/263 (61.6%) |
| Lansoprazole 30 mg | 0/268 (0%) | 3/268 (1.1%) | 113/268 (42.2%) |
| Event | TAK-438 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Duodenal ulcer haemorrhageGastrointestinal disorders | 1/263 | 0/268 |
| PneumoniaInfections and infestations | 0/263 | 1/268 |
| Bladder transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/263 | 1/268 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/263 | 1/268 |
| Event | TAK-438 20 mg | Lansoprazole 30 mg |
|---|---|---|
| Pepsinogen test positiveInvestigations | 124/263 | 28/268 |
| Blood gastrin increasedInvestigations | 97/263 | 20/268 |
| Pepsinogen I increasedInvestigations | 92/263 | 37/268 |
| Upper respiratory tract infectionInfections and infestations | 21/263 | 37/268 |
| DysgeusiaNervous system disorders | 21/263 | 22/268 |
| Protein urine presentInvestigations | 20/263 | 11/268 |
| Alanine aminotransferase increasedInvestigations | 12/263 | 17/268 |
All randomized participants.
| Age, Continuous(years) | TAK-438 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| Mean | 42.0 ± 12.18 | 41.4 ± 12.89 | 41.7 ± 12.53 |
| Sex: Female, Male(Participants) | TAK-438 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| Female | 99 | 92 | 191 |
| Male | 166 | 176 | 342 |
| Race (NIH/OMB)(Participants) | TAK-438 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 265 | 268 | 533 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | TAK-438 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| China | 252 | 255 | 507 |
| Korea, Republic Of | 10 | 8 | 18 |
| Taiwan, Province Of China | 3 | 5 | 8 |
| Height(centimeter (cm)) | TAK-438 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| Mean | 166.1 ± 8.21 | 167.1 ± 8.09 | 166.6 ± 8.16 |
| Weight(kilograms (kg)) | TAK-438 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| Mean | 63.45 ± 12.342 | 64.00 ± 11.383 | 63.72 ± 11.860 |
| Body Mass Index (BMI)(kg/m^2) | TAK-438 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| Mean | 22.87 ± 3.365 | 22.83 ± 3.181 | 22.85 ± 3.270 |
| Smoking Classification(Participants) | TAK-438 20 mg | Lansoprazole 30 mg | Total |
|---|---|---|---|
| The Participant Has Never Smoked | 164 | 165 | 329 |
| The Participant Is a Current Smoker | 86 | 84 | 170 |
| The Participant Is an Ex-smoker | 15 | 19 | 34 |
12 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Apr 2017 to primary completion in Mar 2019, 23 months.
Results were first posted in Jun 2020, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vonoprazan · Lansoprazole